-
AmpliFold Capture-and-Release for LFA Sensitivity
2026-10-06
A ChemRxiv preprint presents AmpliFold, a triggered capture-and-release strategy intended to reduce the kinetic limitations of lateral flow assays by enabling high-affinity rebinding. In a HER2 model, the authors report up to 16-fold improvement in detection limits and a 12-fold sensitivity enhancement with large gold nanoparticles, while noting that the work remains a proof of concept.
-
Cyanidin Chloride: From Identity to Evidence
2026-10-05
Cyanidin Chloride can support sophisticated oxidative stress research, but chemical identity determines how confidently results can be interpreted. This evidence-first analysis separates the product’s aglycone profile from the related glycoside studied in a 2024 psoriasis model and defines meaningful research boundaries.
-
ARCA EGFP mRNA (5-moUTP): Evidence and Context
2026-10-04
ARCA EGFP mRNA (5-moUTP) is presented as a polyadenylated EGFP reporter for assessing mRNA delivery and expression in mammalian cells. This overview separates supplier-described design features from peer-reviewed evidence, compares conventional transcript engineering with newer structural approaches, and explains why fluorescence is useful but not sufficient for judging mRNA performance or therapeutic relevance.
-
Neurotensin: Evidence, Signaling and Study Limits
2026-10-03
A source-grounded overview of Neurotensin, Neurotensin receptor 1 signaling, GPCR trafficking, miR-133α claims, evidence quality, and the limits of applying unrelated fluorescence-classification research to gastrointestinal biology.
-
T0070907 for RXRα/PPARγ Causal Assays
2026-10-02
T0070907 is a covalent PPARγ antagonist for testing receptor-dependent transcription, adipogenesis, and cancer phenotypes. This article develops a causal assay framework that connects PPARγ/RXRα heterodimer modulation with the RXRα/PPARγ/NEDD4 pathway in atherosclerosis.
-
Bufalin–CRISPR Nanomedicine in Colorectal Cancer
2026-10-01
A 2025 Materials Today Bio study describes calcium lactate nanoparticles that co-deliver bufalin and a CD47-targeting CRISPR/Cas9 ribonucleoprotein to combine tumor-cell killing with macrophage reprogramming. The reported design links pyroptosis, apoptosis, reduced antiphagocytic signaling, and M1 macrophage activity into a coordinated preclinical immunotherapy strategy.
-
EdU, BaP, and the Translational Cell-Cycle Signal
2026-10-01
BaP-driven prostate cancer progression illustrates why DNA synthesis, immune context, and tumor growth must be measured together. This thought-leadership article explains how EdU-based flow cytometry can strengthen mechanistic studies, pharmacodynamic decisions, and genotoxicity testing while clarifying the limits of proliferation-only readouts.
-
IR-820: New Indocyanine Green Imaging Workflows
2026-09-30
IR-820 (New Indocyanine Green) supports reproducible near-infrared fluorescence imaging across vascular mapping, tumor localization, and diseased tissue quantification. This guide translates the optical properties of the free dye into practical workflows while distinguishing validated imaging use from exploratory nanoparticle and photothermal applications.
-
AngII Drives M1 Polarization via Cx43/NF-κB
2026-09-30
The reference study identifies connexin 43 and NF-κB signaling as a mechanistic link between angiotensin II exposure and pro-inflammatory M1 polarization in RAW264.7 macrophages. Its combined molecular profiling and inhibitor-based design provides a useful framework for studying Cx43-dependent inflammation while also highlighting the need to distinguish macrophage findings from evidence in neuroglial and ischemic models.
-
Viral RIPK3 Degradation and Neddylation Biology
2026-09-29
The reference study identifies a cowpox virus and orthopoxvirus strategy that recruits SCF machinery to target RIPK3 for ubiquitin-proteasome degradation, thereby reshaping necroptosis, inflammation, and viral pathogenesis. Its combination of screening, viral genetics, and mouse infection models provides a framework for studying how host-directed protein degradation influences infection outcomes.
-
AP20187 for Causal Control of Immune Signaling
2026-09-29
AP20187 is a chemical inducer of dimerization that can convert descriptive immune observations into experimentally testable causal models. This article connects conditional protein activation with chronic intermittent hypoxia research while defining assay controls, handling requirements, and translational limits.
-
Losmapimod: Rethinking p38 Inhibition in Translation
2026-09-28
Losmapimod offers translational researchers a well-characterized way to interrogate p38α/β signaling across inflammatory and vascular models. New structural work on p38α dephosphorylation adds an important design question—but does not establish that Losmapimod shares the reported dual-action mechanism.
-
DiscoveryProbe Natural Product Library Plus: Assay Logic
2026-09-27
The DiscoveryProbe Natural Product Library Plus supports diverse, automation-ready screening, but a strong hit is only the start of a mechanistic argument. This article explains how to connect enzyme inhibition to parasite-cell effects while accounting for assay interference, target attribution, and selectivity.
-
LBP Restores Muscle Mitochondrial Quality in Obesity
2026-09-26
Ren et al. report that Lycium barbarum polysaccharide (LBP) improves high-fat-diet-associated skeletal muscle changes alongside AMPK/PINK1/Parkin-mediated mitophagy. Inhibitor and Parkin-knockdown experiments support a role for this pathway, while the findings remain preclinical and do not establish LBP as a treatment for human sarcopenic obesity.
-
Plk1 Control of p31comet in Checkpoint Disassembly
2026-09-26
Kaisari and colleagues show that Polo-like kinase 1 (Plk1) phosphorylates p31comet at S102 and suppresses its cooperation with TRIP13 in disassembling mitotic checkpoint complexes. The work identifies a regulatory brake that may help preserve checkpoint activity while it is needed, while also suggesting specific biochemical readouts for studying checkpoint silencing.